EVENT – Talk Bio

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

1 week ago talkbio0Tagged Adverse event, ATTR-CM, Event, Gene Modification, gene therapy, Intellia, liver transaminase, MAGNITUDE trial, Response process, Safety, Stock Decline

Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response

Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships

2 months ago talkbio0Tagged Awareness, Basketball game, Eli Lilly, Event, Madness, Malignant neoplasm of breast, Woman

Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

4 months ago talkbio0Tagged AK006, Allakos, chronic, Clinical Trials, Dermatitis, Atopic, Failure (biologic function)

Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

4 months ago talkbio0Tagged AK006, Allakos, Biotechnology, Chronic Spontaneous Urticaria, Failure (biologic function), Financial cost, phase 1 trial, restructuring, strategic alternatives

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.

Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform

5 months ago talkbio0Tagged Autoimmune Diseases, GEM, GEM-DIMER, HB2198, Hinge Bio, immune reset, Lupus Erythematosus, Systemic, Series

Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus

Denali Therapeutics Faces Another Setback in ALS Treatment Development

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Denali, DNL343, Failure (biologic function), HEALEY, Phase II/III trial, Platform trial

Denali Therapeutics, ALS, Phase II/III trial, HEALEY ALS Platform trial, DNL343, treatment failure

Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines

6 months ago talkbio0Tagged Adult, Bioscience, DKK1 gene, next-generation, PCV21, PCVs, Pediatric brand name, Phase III Testing, pneumococcal conjugate, sanofi, Vaccines

Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

6 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile

6 months ago talkbio0Tagged Biclonics, Cancer of Neck, Clinical Trials, Congress (U.S. Legislature), Epidermal Growth Factor Receptor, ESMO, LGR5 gene, Merus, Petosemtamab

Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

7 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies